Search results for " Drug"

showing 10 items of 3138 documents

Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage

1994

Abstract For patients undergoing dialysis with a high risk of haemorrhage there is no standardized procedure for anticoagulation during extracorporeal circulation. Minimal heparinization with a dose equivalent to half that used for chronic haemodialysis was employed in 49 patients (125 haemodialyses) performed after operative interventions (83.3%), after haemorrhagic events (5.2%) and after invasive investigations (11.5%). Using a biocompatible membrane and a low molecular weight heparin (bolus dose 500-1300 U; continuous infusion 100-400 U) it was possible to complete haemodialysis in 74 cases (Group 0) without clots appearing in the venous bubble trap of the tubing system. In 30 cases (Gr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntithrombin IIILow molecular weight heparinHemorrhageFibrin Fibrinogen Degradation ProductsClinical ProtocolsRenal DialysisRisk FactorsmedicineHumansIn patientRisk factorDialysisAgedMonitoring PhysiologicDose-Response Relationship Drugbusiness.industryAnticoagulantExtracorporeal circulationHematologyGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedAntifibrinolytic AgentsSurgeryFemaleHemodialysisbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Nonlinear pharmacokinetics of fluvoxamine and gender differences.

1998

This prospective study assessed fluvoxamine serum concentrations under two different fixed doses. The study included 15 male and female patients who met the DSM-III-R criteria for major depression. They were prescribed 50 mg fluvoxamine twice a day for 2 weeks and 100 mg twice a day thereafter. Drug monitoring was carried out on days 14 and 28. Fluvoxamine serum concentrations were highly variable between patients. After the dose was doubled, the serum concentrations of fluvoxamine increased disproportionately (mean, 3.4-fold), and there was a significantly (p < 0.05) more pronounced increase in men (4.6-fold) than in women (2.4-fold). These results provide evidence of nonlinear, sex-depend…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentFluvoxamineGastroenterologySex FactorsPharmacokineticsOral administrationInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyAgedPharmacologyAged 80 and overChemotherapyDepressive DisorderDose-Response Relationship Drugbusiness.industryNonlinear pharmacokineticsMiddle AgedDose–response relationshipFluvoxamineAnesthesiaAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugTherapeutic drug monitoring
researchProduct

Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure

2003

Abstract Background/Aims Except for bleeding complications, other serious adverse reactions of coumarin anticoagulants such as hepatotoxicity or skin necrosis are comparatively rare. Nonetheless, a small number of coumarin-induced (sub-) acute liver failures has been published. Methods A retrospective analysis was performed of patients treated for liver disease between 1992 and 2002 at our department to evaluate the incidence, clinical findings and histopathology of coumarin-induced hepatotoxicity. Results The retrospective analysis revealed eight cases of phenprocoumon-induced hepatotoxicity, including three cases of (sub-) acute liver failure which resulted in two orthotopic liver transpl…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexGastroenterologyPhenprocoumonLiver diseaseGermanyInternal medicinemedicineHumansAdverse effectRetrospective StudiesHepatitisLiver injuryHepatologybusiness.industryLiver cellAnticoagulantsLiver Failure AcuteMiddle Agedmedicine.diseaseSurgeryAcute DiseasePhenprocoumonFemaleChemical and Drug Induced Liver InjuryComplicationbusinessmedicine.drugJournal of Hepatology
researchProduct

Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum

2004

Mirtazapine is a novel antidepressant that acts by enhancing serotonergic and noradrenergic neurotransmission. Because very little is known about serum concentrations in relation to clinical effects, the use of therapeutic drug monitoring is so far unclear. A rapid automated HPLC method with fluorescence detection was developed for routine quantification of mirtazapine and its demethylated metabolite N-desmethylmirtazapine in human serum. The precision of the method was suitable because the day-to-day (n = 7) coefficient of variation (CV) of mirtazapine was 9.8, 4.2, and 5.1% for concentrations of 10, 40, and 80 ng/mL, respectively, and the CV for N-desmethylmirtazapine were 11.6, 10.3, and…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentMetaboliteCoefficient of variationMirtazapineMirtazapineMianserinPharmacologySensitivity and Specificitychemistry.chemical_compoundInternal medicinemedicineHumansPharmacology (medical)AmisulprideAntipsychoticChromatography High Pressure LiquidAgedPharmacologySertralinemedicine.diagnostic_testbusiness.industryMiddle AgedEndocrinologychemistryTherapeutic drug monitoringHistamine H1 AntagonistsAntidepressantFemaleDrug Monitoringbusinessmedicine.drugTherapeutic Drug Monitoring
researchProduct

Efficacy and tolerability of multiple-dose SDZ IMM 125 in patients with severe psoriasis.

2006

Although cyclosporin is effective in immunosuppression following organ transplantation and in the treatment of psoriasis, its use is limited by its side-effects, notably impaired renal function and hypertension. As SDZ IMM 125, a new derivative of the cyclosporin family, showed considerable immunosuppressive activity in experimental studies, with less effect on renal function, it was considered a potential successor to cyclosporin for both indications. In this multicentre, double-blind, placebo-controlled study, the efficacy and tolerability of 40, 100, 200 and 400 mg SDZ IMM 125 daily were studied in 59 patients with psoriasis. Patients were followed for a period of 5 weeks (4 weeks treatm…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentRenal functionCyclosporinsDermatologyPharmacologyGastroenterologyDrug Administration ScheduleDouble-Blind MethodInternal medicinePsoriasismedicineHumansPsoriasisAdverse effectBody surface areaChemotherapyDose-Response Relationship Drugbusiness.industryImmunosuppressionMiddle Agedmedicine.diseaseTolerabilityToxicityFemalebusinessImmunosuppressive AgentsFollow-Up StudiesThe British journal of dermatology
researchProduct

Fluoroquinolone-induced liver injury: three new cases and a review of the literature.

2012

PURPOSE: Fluoroquinolones are popular and widely used in primary care and hospital settings. Premarketing studies showed a favourable side-effect profile. However, significant morbidity and the need for liver transplantation for acute liver failure have been reported. We reviewed the available data on liver damage linked to fluoroquinolones. METHODS: A systematic search of case reports on the MEDLINE database encompassing the years 2000-2011 was carried out. Additional references were found by a manual search of the retrieved paper. We also describe three new cases of hepatotoxicity attributable to fluoroquinolones seen at our Unit. RESULTS: Thirty-five cases were retrieved from MEDLINE (51…

AdultMalemedicine.medical_specialtymedicine.medical_treatmentTreatment outcomePrimary careLiver transplantationfluoroquinoloneSeverity of Illness IndexSeverity of illnessMedicineHumansPharmacology (medical)Liver damageIntensive care medicinePharmacologyHepatitisLiver injurySettore MED/12 - Gastroenterologiabusiness.industryLiver failureGeneral MedicineMiddle Agedmedicine.diseaseAnti-Bacterial AgentsTreatment OutcomeItalyliver damageSettore BIO/14 - FarmacologiaFemaleDILIChemical and Drug Induced Liver InjurybusinessFluoroquinolones
researchProduct

Effects of post-extinction l-DOPA administration on the spontaneous recovery and reinstatement of fear in a human fMRI study

2015

Relapse is a pertinent problem in the treatment of anxiety disorders. In the laboratory, relapse is modeled as return of conditioned fear responses after successful fear extinction and is explained by insufficient retrieval and/or expression of the fear-inhibitory extinction memory that is generated during extinction learning. We have shown in mice and humans that return of fear can be prevented by administration of a single dose of the dopamine precursor l-3,4-dihydroxyphenylalanine (l-DOPA) immediately after extinction. In mice, this effect could be attributed to an enhancement of extinction memory consolidation. In our human study, we could not exclude that l-DOPA might have acted by int…

AdultMalemedicine.medical_treatmentDopamine AgentsSpontaneous recoveryExposure therapyVentromedial prefrontal cortexAmygdalaFear-potentiated startleExtinction PsychologicalDevelopmental psychologyLevodopaRandom AllocationDouble-Blind MethodConditioning PsychologicalmedicineHumansPharmacology (medical)Fear conditioningBiological PsychiatryMemory ConsolidationPharmacologyFear processing in the brainBrain MappingPsychotropic DrugsBrainFearGalvanic Skin Responsesocial sciencesExtinction (psychology)Magnetic Resonance ImaginghumanitiesPsychiatry and Mental healthmedicine.anatomical_structureNeurologyVisual PerceptionNeurology (clinical)CuesPsychologyNeuroscienceEuropean Neuropsychopharmacology
researchProduct

Long term structural effects of combination therapy in patients with early rheumatoid arthritis: five year follow up of a prospective double blind co…

2003

Objective: To evaluate whether early combined therapy with methotrexate (MTX) and sulfasalazine (SSZ) during the first year in early rheumatoid arthritis (RA) induces long term beneficial effects, compared with monotherapy, when the further treatment strategy is a free choice. Methods: Study design: five year multicentre prospective longitudinal trial. Participants: 146/205 patients with RA previously included in a one year prospective randomised trial comparing the effects of treatment with MTX, SSZ, or a combination of both. Criteria for inclusion: patients with early RA (⩽1 year duration). Follow up: between the end of years 1 and 5, patients were followed up and treated by their own rhe…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtyConcise ReportCombination therapymedicine.medical_treatmentImmunologyArthritisSeverity of Illness IndexGeneral Biochemistry Genetics and Molecular Biologylaw.inventionArthritis RheumatoidDouble-Blind MethodRheumatologyRandomized controlled triallawSulfasalazineInternal medicinemedicineHumansImmunology and AllergyProspective StudiesDisease-modifying antirheumatic drugskin and connective tissue diseasesProspective cohort studyAgedAnalysis of Variancebusiness.industryMiddle Agedmedicine.diseaseSurgerySulfasalazineClinical trialMethotrexateTreatment OutcomeAntirheumatic AgentsRheumatoid arthritisDrug Therapy CombinationFemalebusinessFollow-Up Studiesmedicine.drugAnnals of the Rheumatic Diseases
researchProduct

Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report

2009

This is a preliminary report on a case-series of rheumatoid patients that underwent various kinds of elective surgery but did not withdraw etanercept therapy in spite of physician advise. Elective surgery consisted of right knee surgical prosthesis, bilateral cataract, bilateral hallux valgus, right hip prosthesis, bladder stone by cystoscopy and left inguinal hernia. All the patients had a regular healing rate. During follow-up (6-12 months) no one of these patients were suffering from infective complications after surgery. According to same recent literature results, our data suggest that it is the time to value rheumatoid patient preferences through a correct information about cost-benef…

AdultMalemusculoskeletal diseasesmedicine.medical_specialtySettore MED/09 - Medicina InternaPilot ProjectsReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidPostoperative ComplicationsPatient satisfactionRheumatologyInternal medicinemedicineHumansPostoperative PeriodElective surgeryWound Healingmedicine.diagnostic_testTumor Necrosis Factor-alphabusiness.industryContraindicationsGeneral MedicineCystoscopyMiddle Agedmedicine.diseaseRheumatologySurgerySettore MED/16 - ReumatologiaTolerabilityElective Surgical ProceduresImmunoglobulin GRheumatoid arthritisFemaleBiological therapy Decompensated diabetes mellitus Etanercept Polymyalgia rheumatica Steroid therapy.businessAdverse drug reactionmedicine.drugClinical Rheumatology
researchProduct

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct